CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing GLIX1, a novel therapeutic targeting a newly identified mechanism in cancer cells, specifically for treating Glioblastoma Multiforme. Initial studies show that GLIX1 significantly outperforms existing treatments in killing cancer cells and reducing tumor growth in animal models, pavin…
Glioblastoma Multiform (GBM) patients usually die 12-18 months after diagnosis, with a 5-year survival rate of 6.8%.
There are only 5 therapies approved to treat GBM and all of them provide marginal improvements of <9 months to patients’ survival.
With a clinical pipeline that is constantly failing (last approval in 2004) and the lack of effective therapies, GBM remains the highest unmet need in oncology.After years of research, we discovered the GLIX family, which targets a newly discovered mec…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
